Evidence map›Paper›PMID 41506775›Full record

ArticleBMJ open2026

Association of influenza viral genetic information with severity markers in patients hospitalised with influenza: multicentre retrospective cohort study.

Aung Pone Myint, George Shirreff, Vicky Baillie, Antonin Bal, Celina F Boutros, Elena Burtseva, Daouda Coulibaly, Daria Danilenko, Ghassan Dbaibo, Gregory Destras and 31 more

Abstract readMulticenter Study
In one paragraph

Article in BMJ open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

41 authors.

Aung Pone MyintUniversité Claude Bernard Lyon 1, Villeurbanne, France.ORCID http://orcid.org/0000-0002-5603-8724
George ShirreffCentre of Excellence in Respiratory Pathogens (CERP), Hospices Civils de Lyon (HCL) and Centre International de Recherche en Infectiologie (CIRI), Équipe Santé Publique, Épidémiologie et Écologie Évolutive des Maladies Infectieuses (PHE3ID), Inserm U1111, CNRS UMR5308, ENS de Lyon, Université Claude Bernard Lyon 1 (UCBL Lyon 1), Lyon, France.
Vicky BaillieSouth African Medical Research Council, Vaccines and Infectious Diseases Analytics (VIDA) Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
Antonin BalHCL and CIRI, Inserm U1111, CNRS UMR5308, ENS de Lyon, UCBL Lyon 1, Lyon, France.
Celina F BoutrosAmerican University of Beirut Centre for Infectious Diseases Research, Beirut, Beirut Governorate, Lebanon.
Elena BurtsevaGamaleya National Research Centre for Epidemiology and Microbiology, Ministry of Health of Russian Federation, Moscow, Russian Federation.
Daouda CoulibalyInstitut National d'Hygiène Publique, Abidjan, Côte d'Ivoire.
Daria DanilenkoSmorodintsev Research Institute of Influenza, Saint Petersburg, Russian Federation.
Ghassan DbaiboCentre for Infectious Diseases Research, American University of Beirut, Beirut, Lebanon.
Gregory DestrasHCL and CIRI, Inserm U1111, CNRS UMR5308, ENS de Lyon, UCBL Lyon 1, Lyon, France.
Ndongo DiaInstitut Pasteur of Dakar, Dakar, Senegal.
Anca Cristina DrăgănescuNational Institute of Infectious Diseases Prof Dr Matei Bals, Bucharest, Romania.
Heloisa I G GiamberardinoHospital Pequeno Principe, Curitiba, Paraná, Brazil.
Andrey B KomissarovSmorodintsev Research Institute of Influenza, Saint Petersburg, Russian Federation.
Parvaiz A KoulSher-i-Kashmir Institute, Srinagar, Jammu and Kashmir, India.
Victor Alberto Laguna-TorresClínica Internacional, Instituto de Medicina Tropical, Universidad Nacional Mayor de San Marcos, Lima District, Lima Region, Peru.
Jason J LeBlancDalhousie University, Halifax, England, Canada.
Ainara Mira-IglesiasFISABIO, Valencia, Valencian Community, Spain.
Alla MironenkoSI Kyiv City Centre for Diseases Control and Prevention of the Ministry of Health of Ukraine, Kyiv, Ukraine.
Alejandro Orrico-SánchezFISABIO, Valencia, Valencian Community, Spain.
Nancy A OtienoKenya Medical Research Institute, Kisumu, Kenya.
Oana SăndulescuCarol Davila University of Medicine and Pharmacy, National Institute for Infectious Diseases "Prof. Dr. Matei Balș", Bucuresti, Bucuresti, Romania.ORCID http://orcid.org/0000-0002-2586-4070
Viviana SimonIcahn School of Medicine at Mount Sinai, New York, New York, USA.
Anna SomininaSmorodintsev Research Institute of Influenza, Saint Petersburg, Russian Federation.
Emilia SordilloIcahn School of Medicine at Mount Sinai, New York, New York, USA.
Mine Durusu TanrioverVaccine Institute, Hacettepe University, Ankara, Ankara, Turkey.
Nataliia TeteriukSI Kyiv City Centre for Diseases Control and Prevention of the Ministry of Health of Ukraine, Kyiv, Ukraine.
Serhat UnalDepartment of Infectious Diseases and Clinical Microbiology, Hacettepe University School of Medicine, Ankara, Turkey.
Harm Van BakelIcahn School of Medicine at Mount Sinai, New York, New York, USA.
Melissa K AndrewDalhousie University, Halifax, England, Canada.
Joseph BreseePartnership for International Vaccine Initiatives, The Task Force for Global Health, Decatur, Georgia, USA.
Bruno LinaHCL and CIRI, Inserm U1111, CNRS UMR5308, ENS de Lyon, UCBL Lyon 1, Lyon, France.
F Xavier López-LabradorFISABIO, Valencia, Valencian Community, Spain.
Justin R OrtizCentre for Vaccine Development and Global Health, University of Maryland Baltimore School of Medicine, Baltimore, Maryland, USA.
Sonia M RaboniMolecular Biology/Microbiology Research Laboratory, Universidade Federal do Paraná, Curitiba, Paraná, Brazil.ORCID http://orcid.org/0000-0001-7907-7585
Wenqing ZhangGlobal Influenza Program, World Health Organization, Geneve, Switzerland.
Sandra S ChavesFoundation for Influenza Epidemiology, Fondation de France, Paris, Île-de-France, France.
Giacomo CacciapagliaLaboratoire de Physique Théorique et Hautes Energies (LPTHE), UMR 7589, Sorbonne Université and CNRS, Paris, France.
Laurence JossetHCL and CIRI, Inserm U1111, CNRS UMR5308, ENS de Lyon, UCBL Lyon 1, Lyon, France.
Cécile ChauvelCentre of Excellence in Respiratory Pathogens (CERP), Hospices Civils de Lyon (HCL) and Centre International de Recherche en Infectiologie (CIRI), Équipe Santé Publique, Épidémiologie et Écologie Évolutive des Maladies Infectieuses (PHE3ID), Inserm U1111, CNRS UMR5308, ENS de Lyon, Université Claude Bernard Lyon 1 (UCBL Lyon 1), Lyon, France.
Marta C NunesCentre of Excellence in Respiratory Pathogens (CERP), Hospices Civils de Lyon (HCL) and Centre International de Recherche en Infectiologie (CIRI), Équipe Santé Publique, Épidémiologie et Écologie Évolutive des Maladies Infectieuses (PHE3ID), Inserm U1111, CNRS UMR5308, ENS de Lyon, Université Claude Bernard Lyon 1 (UCBL Lyon 1), Lyon, France marta.nunes@chu-lyon.fr.ORCID http://orcid.org/0000-0003-3788-878X

Funding

World Health Organization 001
6 · The paper itself

Abstract

objectiveThe objective of this study was to determine the association between viral subtype/clade and disease severity.

designMulticentre retrospective cohort study.

settingThis study used data from the Global Influenza Hospital Surveillance Network (GIHSN). The dataset comprised hospitalised influenza patients with viral sequencing data across 14 countries, collected from August 2022 through October 2023.

participantsA total of 761 hospitalised patients were enrolled during the study period, and 745 patients were included in the analysis. We excluded patients with missing data on explanatory or outcome variables, those infected with viral clades represented by fewer than 11 sequences, and those enrolled at study sites contributing fewer than 5 patients. OUTCOME MEASURES: Disease severity was defined by admission to intensive care unit (ICU), receipt of non-invasive oxygen supplementation, 3-variable definition (ICU, mechanical ventilation or death) or 4-variable definition (3-variable plus oxygen supplementation).Outcomes were analysed in association with subtype or clade using the mixed-effects logistic regression models, adjusting for age group, sex, underlying medical conditions, influenza vaccination status, antiviral use, country income level and epidemic period, while study site was included as a random effect.

results745 patients were included: 263 A(H1N1)pdm09, 380 A(H3N2), 102 B/Victoria. A(H1N1)pdm09 infection was associated with increased odds of ICU admission (adjusted ORs (aORs) 2.5, 95% CI 1.1 to 5.8) compared with A(H3N2). 6B.1A.5a.2a.1 clade of A(H1N1)pdm09 was associated with increased severity compared with 6B.1A.5a.2a clade (aOR 3.0, 95% CI 1.0 to 9.5) and (aOR 5.4, 95% CI 1.6 to 18.3) for the 3-variable and 4-variable definitions respectively. Among A(H3N2), the (3C.2a1b.2a.)2b clade showed a trend toward increased severity using the 4-variable definition compared with the 2a.1b clade (aOR 2.9, 95% CI 0.8 to 10.0).

conclusionsThis analysis highlights the differential impact of influenza subtypes and clades on disease severity in hospitalised patients. Future research should investigate the role of specific viral mutations of these clades in modulating immune evasion or disease severity. These findings reinforce the GIHSN's critical role in global surveillance. Ongoing genomic surveillance is crucial for understanding the clinical impact of emerging influenza variants and informing public health responses.

Indexed as

Influenza, HumanAdolescentAdultAgedChildFemaleHospitalizationHumansInfluenza A Virus, H1N1 SubtypeInfluenza A Virus, H3N2 SubtypeIntensive Care UnitsMaleMiddle AgedRetrospective StudiesSeverity of Illness IndexYoung AdultEpidemicsEpidemiologyEPIDEMIOLOGYINFECTIOUS DISEASESRespiratory infections

Identifiers

PMID41506775
PMCPMC13059944

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.